logo

For the Inventor, By the Inventor

Daejeon, South Korea

Pharmabcine Inc.

Calculating rank
USPTO Granted Patents = 11


Forward Citations = 9

Loading Chart...
Loading Chart...

72 inventors (with patents filed for the assignee):

goldMedal Weon Sup Lee (8 out of 8 patents)

silverMedal Jin-San Yoo (7 out of 8 patents)

bronzeMedal Sang Soon Byun (6 out of 6 patents)

4.  Sung-Woo Kim (5 out of 9 patents)

5.  Sang Ryeol Shim (5 out of 5 patents)

6.  Youngae Lee (4 out of 4 patents)

7.  Jae Bong Yoon (4 out of 5 patents)

8.  Do-Yun Kim (4 out of 7 patents)

9.  Jin San Yoo (4 out of 4 patents)

10.  Hyuk Jin Lee (4 out of 18 patents)

11.  Miju Park (3 out of 3 patents)

12.  Eun Hee Lee (3 out of 6 patents)

13.  Jinsang Yoo (3 out of 3 patents)

14.  Do-yun Kim (3 out of 3 patents)

15.  Chae-Ok Yun (3 out of 12 patents)


11 patents:

1. 12473366 - ANTI-TIE2 ANTIBODY AND USE THEREOF (2025-11-18),
2. 11407834 - Anti-PD-L1 antibody and use thereof (2022-08-09),
3. 11407833 - Anti-VISTA antibody and use thereof (2022-08-09),
4. 10597457 - EGFRvIII antibody and composition comprising same (2020-03-24),
5. 10155817 - Dual-target antibody targeting VEGFR-2 and DLL4 and pharmaceutical composition including same (2018-12-18),
6. 10125194 - Dual targeting antibody of novel form, and use thereof (2018-11-13),
7. 10106622 - Human antibody specific to c-Met and preparation method thereof (2018-10-23),
8. 9963512 - Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same (2018-05-08),
9. 9249220 - Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof (2016-02-02),
10. 9249219 - Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof (2016-02-02),
11. 9150650 - Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof (2015-10-06),
Company Overview
Pharmabcine Inc. is a biotechnology company based in Daejeon, South Korea, focused on the development of innovative therapies for cancer treatment. The company specializes in the research and production of monoclonal antibodies and other biologics, leveraging advanced technologies to enhance therapeutic efficacy. Pharmabcine is committed to addressing unmet medical needs through its cutting-edge research initiatives, aiming to improve patient outcomes in oncology and related fields.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

11 Patents

#61 in Daejeon

#1,011 in South Korea

#51,873 in the World

Daejeon, KR
Daejeon, South Korea

Pharmabcine Inc.

Forward Citations = 9

72 inventors:

goldMedal Weon Sup Lee (8 out of 8 patents)

silverMedal Jin-San Yoo (7 out of 8 patents)

bronzeMedal Sang Soon Byun (6 out of 6 patents)

4.  Sung-Woo Kim (5 out of 9 patents)

5.  Sang Ryeol Shim (5 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Pharmabcine Inc.. Retrieved from https://idiyas.com/company/pharmabcine

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…